Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin
复制标题
DOI：
10.1182/blood-2002-05-1447
复制
发表时间：
2003-01-15
期刊：
影响因子：
20.3
通讯作者：
Kaveri, SV
中科院分区：
文献类型：
--
作者：
Bayry, J;Lacroix-Desmazes, S;Kaveri, SV
用于治疗的正常免疫球蛋白G（静脉注射免疫球蛋白[IVIg]）越来越多地用于免疫介导的疾病，包括急性和慢性/复发性自身免疫性疾病、移植和全身性炎症性疾病。几种相互不排斥的作用机制解释了IVIg的免疫调节作用。尽管IVIg抑制T细胞增殖和T细胞细胞因子的产生，但尚不清楚这些作用是直接依赖于IVIg对T细胞的作用，还是通过抑制抗原提呈细胞活性来依赖。在这里，我们研究了IVIg对树突状细胞（dc）分化、成熟和功能的影响。我们发现IVIg在体外抑制DC的分化和成熟，并在激活时消除成熟DC分泌白细胞介素-12 （IL-12）的能力，同时增强IL-10的产生。ivig诱导的与细胞因子分泌调节相关的共刺激分子的下调导致自身反应性和同种异体反应性t细胞活化和增殖的抑制。IVIg对DC成熟和功能的调节可能与其在自身免疫性疾病、移植和其他免疫介导疾病中控制特异性免疫反应的免疫调节作用相关。(C) 2003年由美国血液病学会出版。
Normal immunoglobulin G for therapeutic use (intravenous immunoglobulin [IVIg]) is used in an increasing number of immune-mediated conditions, including acute and chronic/relapsing autoimmune diseases, transplantation, and systemic inflammatory disorders. Several mutually nonexclusive mechanisms of action account for the immunoregulatory effects of IVIg. Although IVIg inhibits T-cell proliferation and T-cell cytokine production, it is unclear whether these effects are directly dependent on the effects of IVIg on T cells or they are dependent through the inhibition of antigen-presenting cell activity. Here, we examined the effects of IVIg on differentiation, maturation, and function of dendritic cells (DCs). We show that IVIg inhibits the differentiation and maturation of DCs in vitro and abrogates the capacity of mature DC to secrete interleukin-12 (IL-12) on activation while enhancing IL-10 production. IVIg-induced down-regulation of costimulatory molecules associated with modulation of cytokine secretion resulted in the inhibition of autoreactive and alloreactive T-cell activation and proliferation. Modulation of DC maturation and function by IVIg is of potential relevance to its immunomodulatory effects in controlling specific immune responses in autoimmune diseases, transplantation, and other immune-mediated conditions. (C) 2003 by The American Society of Hematology.